Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18758187 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2HSD17B10POLBTSHRCASP1 | |
| SCHEMBL17930116 | 0.86 | HPGD (0.41) | SMN1; SMN2HSD17B10POLBTSHRCYP3A4 | |
| SCHEMBL12660032 | 0.86 | HPGD (0.41) | SMN1; SMN2HSD17B10POLBTSHRCYP3A4 | |
| SCHEMBL13623673 | 0.85 | TLR2 (0.40) | HSD17B10POLBTSHRCYP3A4CYP2C19 | |
| SCHEMBL26331966 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2HSD17B10POLBTSHRCASP1 | |
| SCHEMBL15887137 | 0.84 | POLB (0.39) | SMN1; SMN2HSD17B10POLBTSHRCYP3A4 | |
| SCHEMBL12355354 | 0.83 | HSD17B10 (0.43) | SMN1; SMN2HSD17B10POLBTSHRCASP1 | |
| SCHEMBL26031804 | 0.82 | ALDH1A1 (0.39) | SMN1; SMN2HSD17B10POLBTSHRCYP3A4 | |
| SCHEMBL18090282 | 0.82 | POLB (0.39) | SMN1; SMN2HSD17B10POLBTSHRCYP3A4 | |
| SCHEMBL15184870 | 0.81 | TSHR (0.43) | SMN1; SMN2HSD17B10POLBTSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | SMN1; SMN2 2847/4885HSD17B10 1838/4885POLB 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.